Literature DB >> 29254096

Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome.

Patrick J Lao1,2, Ben L Handen3,4,5,6, Tobey J Betthauser1,2, Iulia Mihaila2,7, Sigan L Hartley2,7, Annie D Cohen3, Dana L Tudorascu3,8,9, Peter D Bulova8, Brian J Lopresti10, Rameshwari V Tumuluru3, Dhanabalan Murali1,2, Chester A Mathis10, Todd E Barnhart1, Charles K Stone11, Julie C Price10,12, Darlynne A Devenny13, Sterling C Johnson14, William E Klunk3,15, Bradley T Christian1,2,16.   

Abstract

BACKGROUND: The Down syndrome (DS) population is genetically predisposed to amyloid-β protein precursor overproduction and Alzheimer's disease (AD).
OBJECTIVE: The temporal ordering and spatial association between amyloid-β, glucose metabolism, and gray matter (GM) volume in the DS population can provide insight into those associations in the more common sporadic AD.
METHODS: Twenty-four adults (13 male, 11 female; 39±7 years) with DS underwent [11C]PiB, [18F]FDG, and volumetric MRI scans. Voxel-wise associations between PiB SUVR, FDG SUVR, and GM volume were investigated, with and without individual adjustments for variables of interest.
RESULTS: Positive associations of PiB and age were widespread throughout the neocortex and striatum. Negative associations of FDG and age (frontal, parietal, and temporal cortex) and of GM volume and age (frontal and insular cortex) were observed. PiB and FDG were negatively associated in parietal cortex, after adjustment for GM volume.
CONCLUSIONS: In adults with DS, early amyloid-β accumulation in the striatum is divergent from sporadic AD; however, despite the early striatal amyloid-β, glucose hypometabolism was confined to the typical AD-associated regions, which occurs similarly in autosomal dominant AD. Importantly, the glucose hypometabolism was not explained solely by increased partial volume effect due to GM volume reductions.

Entities:  

Keywords:  Alzheimer’s disease; Down syndrome; Pittsburgh compound B; amyloid-β; fluorodeoxyglucose; glucose metabolism; gray matter; magnetic resonance imaging

Mesh:

Substances:

Year:  2018        PMID: 29254096      PMCID: PMC5994924          DOI: 10.3233/JAD-170720

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  56 in total

Review 1.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

2.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Authors:  Brian J Lopresti; William E Klunk; Chester A Mathis; Jessica A Hoge; Scott K Ziolko; Xueling Lu; Carolyn C Meltzer; Kurt Schimmel; Nicholas D Tsopelas; Steven T DeKosky; Julie C Price
Journal:  J Nucl Med       Date:  2005-12       Impact factor: 10.057

3.  The epidemiology of Alzheimer disease in intellectual disability: results and recommendations from an international conference.

Authors:  W Zigman; N Schupf; M Haveman; W Silverman
Journal:  J Intellect Disabil Res       Date:  1997-02

4.  Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.

Authors:  B Rumble; R Retallack; C Hilbich; G Simms; G Multhaup; R Martins; A Hockey; P Montgomery; K Beyreuther; C L Masters
Journal:  N Engl J Med       Date:  1989-06-01       Impact factor: 91.245

5.  Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.

Authors:  Vincent Doré; Victor L Villemagne; Pierrick Bourgeat; Jurgen Fripp; Oscar Acosta; Gael Chetélat; Luping Zhou; Ralph Martins; Kathryn A Ellis; Colin L Masters; David Ames; Oliver Salvado; Christopher C Rowe
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

6.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

7.  Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.

Authors:  Rebecca L McNamee; Seong-Hwan Yee; Julie C Price; William E Klunk; Bedda Rosario; Lisa Weissfeld; Scott Ziolko; Michael Berginc; Brian Lopresti; Steven Dekosky; Chester A Mathis
Journal:  J Nucl Med       Date:  2009-02-17       Impact factor: 10.057

Review 8.  Nature of mental retardation and dementia in Down syndrome: study with PET, CT, and neuropsychology.

Authors:  M B Schapiro; J V Haxby; C L Grady
Journal:  Neurobiol Aging       Date:  1992 Nov-Dec       Impact factor: 4.673

Review 9.  The neurobiologic consequences of Down syndrome.

Authors:  J T Coyle; M L Oster-Granite; J D Gearhart
Journal:  Brain Res Bull       Date:  1986-06       Impact factor: 4.077

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more
  15 in total

Review 1.  Neuropathological correlates of amyloid PET imaging in Down syndrome.

Authors:  Eric E Abrahamson; Elizabeth Head; Ira T Lott; Benjamin L Handen; Elliott J Mufson; Bradley T Christian; William E Klunk; Milos D Ikonomovic
Journal:  Dev Neurobiol       Date:  2019-08-17       Impact factor: 3.964

2.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

3.  The AT(N) framework for Alzheimer's disease in adults with Down syndrome.

Authors:  Michael S Rafii; Beau M Ances; Nicole Schupf; Sharon J Krinsky-McHale; Mark Mapstone; Wayne Silverman; Ira Lott; William Klunk; Elizabeth Head; Brad Christian; Florence Lai; H Diana Rosas; Shahid Zaman; Melissa E Petersen; Andre Strydom; Juan Fortea; Benjamin Handen; Sid O'Bryant
Journal:  Alzheimers Dement (Amst)       Date:  2020-10-27

4.  Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues.

Authors:  Joshua A Kulas; Whitney F Franklin; Nicholas A Smith; Gunjan D Manocha; Kendra L Puig; Kumi Nagamoto-Combs; Rachel D Hendrix; Giulio Taglialatela; Steven W Barger; Colin K Combs
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-11-13       Impact factor: 4.310

Review 5.  Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome.

Authors:  Alessandra C Martini; Thomas J Gross; Elizabeth Head; Mark Mapstone
Journal:  Neuron       Date:  2022-04-25       Impact factor: 18.688

Review 6.  Dementia in Down syndrome: unique insights for Alzheimer disease research.

Authors:  Ira T Lott; Elizabeth Head
Journal:  Nat Rev Neurol       Date:  2019-03       Impact factor: 42.937

Review 7.  Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis.

Authors:  Elizabeth Head; David K Powell; Frederick A Schmitt
Journal:  Front Aging Neurosci       Date:  2018-06-21       Impact factor: 5.750

8.  Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome.

Authors:  Mark Mapstone; Thomas J Gross; Fabio Macciardi; Amrita K Cheema; Melissa Petersen; Elizabeth Head; Benjamin L Handen; William E Klunk; Bradley T Christian; Wayne Silverman; Ira T Lott; Nicole Schupf
Journal:  Alzheimers Dement (Amst)       Date:  2020-04-05

9.  Psychiatric illness and regression in individuals with Phelan-McDermid syndrome.

Authors:  Teresa M Kohlenberg; M Pilar Trelles; Brittany McLarney; Catalina Betancur; Audrey Thurm; Alexander Kolevzon
Journal:  J Neurodev Disord       Date:  2020-02-12       Impact factor: 4.025

Review 10.  Further understanding the connection between Alzheimer's disease and Down syndrome.

Authors:  Heather M Snyder; Lisa J Bain; Adam M Brickman; Maria C Carrillo; Anna J Esbensen; Joaquin M Espinosa; Fabian Fernandez; Juan Fortea; Sigan L Hartley; Elizabeth Head; James Hendrix; Priya S Kishnani; Florence Lai; Patrick Lao; Cynthia Lemere; William Mobley; Elliott J Mufson; Huntington Potter; Shahid H Zaman; Ann-Charlotte Granholm; H Diana Rosas; Andre Strydom; Michelle Sie Whitten; Michael S Rafii
Journal:  Alzheimers Dement       Date:  2020-06-16       Impact factor: 16.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.